CMTTdb

An integrated database for cancer molecular targeted thearpies

Entry Detail


General information
Database:DB00211
Objective:Thisphase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapynaive metastatic, castrationresistant prostate cancer (mCRPC) patients.
Authors:Zurita AJ,
Title:Sunitinib in combination with docetaxel and prednisone in chemotherapynaive patients with metastatic, castrationresistant prostate cancer: a phase 1/2 clinical trial.
Journal:Ann Oncol.
Year:2012
PMID:21821830
Trial Design
Clinical Trial Id:NCT00137436
Agent:sunitinib
Target:FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor
Cancer Type:prostate cancer
Cancer Subtype:advanced castrationresistant prostate cancer
Therapy Type:com
Therapeutic Combination Type:2
Therapeutic Combination Content:Sunitinib+docetaxel+prednisone
Study Type:a phase I/II clinical trial
Key Patients Feature:chemotherapynaive male patients with metastatic, castrationresistant prostate cancer
Biomarker:PSA
Biomark Analysis:Serum prostatespecific antigen levels were prospectively monitored as a biomarker for cancer activity.
Control Group Info:single arm
Treatment Info:25 patients in four dose escalation cohorts received 3week cycles of sunitinib (2 weeks on, 1 week off), docetaxel and prednisone, preceded by a 4week sunitinib 50 mg/day lead in. RP2D was evaluated in 55 additional patients.
Primary End Point:prostatespecific antigen (PSA) response rate.
Secondary End Point:NA
Patients Number:80
Trial Results
DLT_MTD:Onephase 1 doselimiting toxicity occurred (grade 3 hyponatremia). The RP2D was sunitinib 37.5 mg/day, docetaxel 75 mg/m(2) and prednisone 5 mg b.i.d.
Objective Response Rate:confirmed PSA responses occurred in 31 patients [56.4% (95% confidence interval 42.369.7)];Among 33 assessable patients, 14 (42.4%) had confirmed partial response.
Disease Control Rate:Fortyone patients (75%) were treated >3 months, 12 (22%) completed the study (16 cycles) and 43 (78%) discontinued (36% for disease progression and 27% adverse events).
Median Time to Progression:NA
Median PFS A vs. C:12.6 months
Median OS A vs. C:21.7 months
Adverse Event(agent arm):The most frequent treatmentrelated grade 3/4 adverse events were neutropenia (53%; 15% febrile) and fatigue/asthenia (16%).
Conclusions:This combination was moderately well tolerated, with promising response rate and survival benefit, justifying further investigation in mCRPC.